Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

<p>CONSORT Diagram</p>

Збережено в:

Бібліографічні деталі
Автор:	Aurelius Omlin (14971513) (author)
Інші автори:	Richard Cathomas (14971516) (author), Gunhild von Amsberg (14971519) (author), Christoph Reuter (14971522) (author), Susan Feyerabend (14971525) (author), Wolfgang Loidl (14971528) (author), Martin Boegemann (14971531) (author), Anja Lorch (14971534) (author), Axel Heidenreich (14971537) (author), Igor Tsaur (14971540) (author), Julian Larcher-Senn (14971543) (author), Stefan A.J. Buck (14971546) (author), Ron H.J. Mathijssen (14971549) (author), Ulrich Jaehde (14971552) (author), Silke Gillessen (14971555) (author), Markus Joerger (14971558) (author)
Опубліковано:	2025
Предмети:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Chemotherapy Clinical-Stage Research Computational Methods Algorithms Genitourinary Cancers Prostate cancer Pharmacology Pharmacokinetics and pharmacodynamics
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
за авторством: Aurelius Omlin (14971513)
Опубліковано: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
за авторством: Evan C. Chen (15054014)
Опубліковано: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
за авторством: Dwight H. Owen (15034782)
Опубліковано: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
за авторством: Dwight H. Owen (15034782)
Опубліковано: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
за авторством: Dwight H. Owen (15034782)
Опубліковано: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
за авторством: Dwight H. Owen (15034782)
Опубліковано: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
за авторством: Dwight H. Owen (15034782)
Опубліковано: (2025)

Data Sheet 1_Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.docx
за авторством: Yajie He (20323682)
Опубліковано: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
за авторством: Yan Zhou (15053225)
Опубліковано: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
за авторством: Chong Kin Liam (15331321)
Опубліковано: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
за авторством: Zev A. Wainberg (15047031)
Опубліковано: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
за авторством: Elizabeth R. Tucker (15053624)
Опубліковано: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
за авторством: Elizabeth R. Tucker (15053624)
Опубліковано: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
за авторством: Elizabeth R. Tucker (15053624)
Опубліковано: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
за авторством: Elizabeth R. Tucker (15053624)
Опубліковано: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
за авторством: Elizabeth R. Tucker (15053624)
Опубліковано: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
за авторством: Elizabeth R. Tucker (15053624)
Опубліковано: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
за авторством: Michelle L. Mierzwa (14963463)
Опубліковано: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
за авторством: Arun Kanakkanthara (14937731)
Опубліковано: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
за авторством: Arun Kanakkanthara (14937731)
Опубліковано: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
за авторством: Alyssa C. Flint (16676029)
Опубліковано: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
за авторством: Alyssa C. Flint (16676029)
Опубліковано: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
за авторством: Ulka N. Vaishampayan (15051039)
Опубліковано: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
за авторством: Ulka N. Vaishampayan (15051039)
Опубліковано: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
за авторством: Ulka N. Vaishampayan (15051039)
Опубліковано: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
за авторством: Ulka N. Vaishampayan (15051039)
Опубліковано: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
за авторством: Gregory L. Beatty (15087193)
Опубліковано: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
за авторством: Gregory L. Beatty (15087193)
Опубліковано: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
за авторством: Zachary Quinn (15052893)
Опубліковано: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
за авторством: Fabrice Barlesi (15045504)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_edpnv67nl027abs9arqvftkpev